Navigation Links
GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow

ATLANTA, Nov. 7 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announces that its Chief Scientific Advisor Harriet Robinson, Ph.D. has been elected "Fellow of the American Association for the Advancement of Science (AAAS)." Election as a "Fellow" is an honor bestowed upon AAAS members by their peers because of their contributions to advance science or its applications. Emory University professor and Asa Griggs scholar, Dr. Robinson co-founded GeoVax Labs, Inc. and is one of the world's leading HIV/AIDS vaccine scientists.

Recognized by the AAAS section on medical sciences, Dr. Robinson was elected for her outstanding work on retrovirus biology and the development of DNA vaccines with special emphasis on HIV/AIDS vaccines. In addition to her role as GeoVax's Chief Scientific Advisor, Dr. Robinson is chair of the Division of Microbiology and Immunology at Yerkes National Primate Research Center, a professor of microbiology and immunology in Emory University School of Medicine and an investigator in the Emory Vaccine Center.

GeoVax HIV/AIDS vaccine technologies were developed by Dr. Robinson in collaboration with colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC). GeoVax HIV/AIDS vaccines are moving forward in human clinical trials administered by the HIV Vaccine Trials Network (HVTN). Four (4) Phase 1 human trials involving over 115 individuals are currently underway and Phase 2 trials are being planned for 2008.

Licensed by GeoVax, this innovative, two-step vaccine administration strategy utilizes DNA vaccines to prime the human immune system and recombinant MVA vaccines to boost the immune response against the AIDS virus. Both vaccines express greater than 50% of AIDS virus' (HIV-1) components and stimulate an antibody response as well as a T-cell response. Neither vaccine can cause AIDS. Early studies conducted at Emory University demonstrated successful long-term protection against the development of AIDS in non-human primates where 22 of 23 vaccinates were protected against AIDS development for nearly four years (trial concluded).

"Dr. Robinson is an outstanding scientist most deserving of this distinction," said Don Hildebrand, President, CEO and Chairman of GeoVax Labs, Inc. "As a co-founder of GeoVax, Dr. Robinson has been instrumental in the success our company has achieved to date. Her leadership in HIV/AIDS vaccine research is invaluable. I believe her contributions will positively impact the lives of millions of people worldwide."

Dr. Robinson's recognition as AAAS Fellow was announced in the AAAS News & Notes section of the journal Science on 26 October 2007. She will be awarded an official certificate and pin on Saturday, February 16th at the Fellows Forum during the 2008 AAAS Annual Meeting in Boston.

About GeoVax Labs, Inc. (

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.

GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.

GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:

-- Use DNA vaccines to "prime" immune responses and MVA vaccines to

"boost" immune responses against the AIDS virus

-- Vaccinate against more than 50% of AIDS virus components and can not

cause AIDS

-- Protected 22 of 23 (96%) non-human primates against the development of

AIDS for over 3 1/2 years

-- Are manufactured & tested under GMP/GLP - EMEA (EU) and FDA guidelines

-- Satisfactorily completed earlier DNA HIV/AIDS vaccine Phase 1 human


-- Are currently being tested in 4 Human Trials. Two started in 2006, two

in summer 2007

-- Have been demonstrated safe to date in human trials

-- Are demonstrating positive immune responses against HIV in the

majority of vaccine recipients

-- Are in planning stage for a larger Phase 2 human trial in 2008

For further information, contact Don Hildebrand or Jennifer Nelms at (404) 727-0971 or visit

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward- looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Company's Securities and Exchange Commission filings and report.

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
2. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
3. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
4. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
5. New Director of Nursing Practice Named for Nurses Association
6. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
7. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
8. Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions
9. Keith Taft Named General Manager of UltraTape Industries
10. AIUM CEO named among most influential in radiology
11. Top Twenty Health Plan Websites Named by
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology: